Loading the company…
Loading the company…
In the last ten years FDA made 2 decisions for Xenix Medical (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (2). The latest was on 2026-09-14.
| Family | Decisions on record |
|---|---|
| Lumbar fusion | 2 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-09-14 | 510(k) | K262193 | RIVA® Posterior Fixation System with NanoACTIV Surface Technology; RIVA® Anchor Sacroiliac Fixation System with NanoACTIV Surface Technology |
| 2026-02-23 | 510(k) | K253583 | LUX Expandable Lumbar Interbody System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Xenix Medical.
In 2025, Xenix Medical reported engagement with 3 surgeons and other clinicians in the states MedaRep covers, worth $8,031 in consulting, speaking, meals and travel for its device products, the most in Florida ($8,031 to 3). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($8,031, 3 engaged).